Frunevetmab (NV-02) is a felinized anti-nerve growth factor (NGF) monoclonal antibody with a Kd of 20 pM. Frunevetmab can effectively decrease osteoarthritis (OA) pain in cats[1][2].
Frunevetmab (NV-02) 以高亲和力和效力中和 NGF，并且不结合补体[2]。
Frunevetmab (1.0-2.8mg/kg；皮下注射；第 0、28 和 56 天) 对患有自然发生的骨关节炎疼痛和相关的行动障碍和残疾的猫显示出积极的处理效果[1]。
| Animal Model: | Cats with naturally-occurring OA pain and associated mobility impairment and disability[1] |
| Dosage: | 1.0-2.8 mg/kg |
| Administration: | s.c; 3 times at 28-day intervals; on days 0, 28, and 56 |
| Result: | Reliefed the pain from osteoarthritis in cats. |
[1]. Margaret E Gruen, et al. Frunevetmab, a felinized anti-nerve growth factor monoclonal antibody, for the treatment of pain from osteoarthritis in cats. J Vet Intern Med. 2021 Nov;35(6):2752-2762.
[2]. D P Gearing, et al. In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Anti-Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats. J Vet Intern Med. 2016 Jul;30(4):1129-37.